--- title: "Press Release: InnoSer continues to deliver critical in-vivo and in-vitro services - InnoSer" description: InnoSer continues its in-vivo and in-vitro research services to help prevent a full interruption of critical research programs during COVID-19 outbreak. --- [Skip to content](https://resources.innoserlaboratories.com/innoser-news/news/press-release-innoser-continues-to-deliver-critical-in-vivo-and-in-vitro-services#main-content) InnoSer International B.V Open main navigation Close main navigation - [Contact us](https://resources.innoserlaboratories.com/innoser-news/news/press-release-innoser-continues-to-deliver-critical-in-vivo-and-in-vitro-services#contact) [Contact us](https://resources.innoserlaboratories.com/innoser-news/news/press-release-innoser-continues-to-deliver-critical-in-vivo-and-in-vitro-services#contact) Mar 20, 2020 11:28:22 AM # Press Release: InnoSer continues to deliver critical in-vivo and in-vitro services [admin](https://resources.innoserlaboratories.com/innoser-news/author/admin) Share: [facebook-f icon](http://www.facebook.com/share.php?u=https://resources.innoserlaboratories.com/innoser-news/news/press-release-innoser-continues-to-deliver-critical-in-vivo-and-in-vitro-services) [linkedin-in icon](http://www.linkedin.com/shareArticle?mini=true&url=https://resources.innoserlaboratories.com/innoser-news/news/press-release-innoser-continues-to-deliver-critical-in-vivo-and-in-vitro-services) [Twitter icon](https://twitter.com/intent/tweet?url=https://resources.innoserlaboratories.com/innoser-news/news/press-release-innoser-continues-to-deliver-critical-in-vivo-and-in-vitro-services) [pinterest-p icon](http://pinterest.com/pin/create/link/?url=https://resources.innoserlaboratories.com/innoser-news/news/press-release-innoser-continues-to-deliver-critical-in-vivo-and-in-vitro-services) [envelope icon](mailto:?body=https://resources.innoserlaboratories.com/innoser-news/news/press-release-innoser-continues-to-deliver-critical-in-vivo-and-in-vitro-services) **Press release | Leiden, 19 March 2020** ## **InnoSer continues to deliver critical *in-vivo* and *in-vitro* services** #### *COVID-19 restrictions call for attention to prevent fully halting life sciences operations* InnoSer remains committed to continuing its *in-vivo* and *in-vitro* research services in its Leiden and Diepenbeek facilities to help prevent a full interruption of critical research programs – including some with strong links to COVID-19. Jan Bartels, InnoSer’s CEO, underlines the importance of continued operations: “The life sciences sector, like many others, is being hit by the SARS-CoV-2 outbreak, the containment measures and the illness of key staff. We unfortunately hear that some facilities are already forced to stop their operations. Therefore, we make it our responsibility to implement measures not only for the safety of our staff, customers and other stakeholders, but also of the life sciences sector and society as a whole.” By implementing certain restrictions, InnoSer aims to ensure safety within the company. Priority is given to critical activities, only required personnel remain in the facilities, and they follow strict procedures on using protective equipment, social distancing and increased attention to hygiene.  Research programs that are (temporarily) in need of support are invited to contact InnoSer via info@innoserlaboratories.com to discuss available options.   ***About InnoSer*** *Founded in 2012, InnoSer is an innovative and dynamic contract research organization (CRO) supporting discovery and preclinical development of drugs. InnoSer’s offerings include PDXO screening platform for oncology, ADPKD mouse model for nephrology, and validated brain organoid models for Parkinson’s for neurodegenerative diseases. It also provides in-vitro pyrogenicity testing and genetically engineered mice model services like colony management, cryopreservation, sanitation/rederivation and pathology.*   For more information, please contact:  Jan Bartels info@innoserlaboratories.com +32(0)11140768 [News](https://resources.innoserlaboratories.com/innoser-news/tag/news) ## Related posts [![](https://resources.innoserlaboratories.com/hs-fs/hubfs/Imported_Blog_Media/ALS-models-1.png?height=200&name=ALS-models-1.png)](https://resources.innoserlaboratories.com/innoser-news/blog/available-als-in-vivo-models-for-preclinical-research) [Blog](https://resources.innoserlaboratories.com/innoser-news/tag/blog), [Neurology](https://resources.innoserlaboratories.com/innoser-news/tag/neurology) ## [Accelerating ALS Drug Development: InnoSer’s Available In Vivo Models for Preclinical Research](https://resources.innoserlaboratories.com/innoser-news/blog/available-als-in-vivo-models-for-preclinical-research) [Dominika Krakova](https://resources.innoserlaboratories.com/innoser-news/author/dominika-krakova) Jun 20, 2023 5:24:57 PM Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder lacking highly effective... [Read more](https://resources.innoserlaboratories.com/innoser-news/blog/available-als-in-vivo-models-for-preclinical-research) [![](https://resources.innoserlaboratories.com/hs-fs/hubfs/Imported_Blog_Media/Inficure-PR@2x.png?height=200&name=Inficure-PR@2x.png)](https://resources.innoserlaboratories.com/innoser-news/news/innoser-and-inficure-bio-liver-inflammation-fibrosis-mouse-model) [Cardio-Metabolic](https://resources.innoserlaboratories.com/innoser-news/tag/cardio-metabolic), [News](https://resources.innoserlaboratories.com/innoser-news/tag/news) ## [InnoSer and Inficure Bio enter partnership to increase accessibility of translational liver inflammation & fibrosis mouse model](https://resources.innoserlaboratories.com/innoser-news/news/innoser-and-inficure-bio-liver-inflammation-fibrosis-mouse-model) [Casey](https://resources.innoserlaboratories.com/innoser-news/author/casey) Oct 27, 2022 11:45:00 AM October 27th [Read more](https://resources.innoserlaboratories.com/innoser-news/news/innoser-and-inficure-bio-liver-inflammation-fibrosis-mouse-model) [![](https://resources.innoserlaboratories.com/hs-fs/hubfs/Imported_Blog_Media/InnoSer-Blog-and-Socials.png?height=200&name=InnoSer-Blog-and-Socials.png)](https://resources.innoserlaboratories.com/innoser-news/rnd/nano-project-ends-with-promising-results) [ALS](https://resources.innoserlaboratories.com/innoser-news/tag/als), [Grants](https://resources.innoserlaboratories.com/innoser-news/tag/grants), [brain-on-chip](https://resources.innoserlaboratories.com/innoser-news/tag/brain-on-chip), [News](https://resources.innoserlaboratories.com/innoser-news/tag/news), [Neurology](https://resources.innoserlaboratories.com/innoser-news/tag/neurology) ## [Nano+ Project Ends With Promising Results](https://resources.innoserlaboratories.com/innoser-news/rnd/nano-project-ends-with-promising-results) [Casey](https://resources.innoserlaboratories.com/innoser-news/author/casey) May 3, 2021 7:30:05 PM Currently with no known cure, Amyotrophic lateral sclerosis (ALS) is a progressive... [Read more](https://resources.innoserlaboratories.com/innoser-news/rnd/nano-project-ends-with-promising-results) facebook-f icon linkedin-in icon Twitter icon instagram icon - Menu Item 1 - Sub-menu Item 1 - Another Item - Sub-menu Item 2 - Menu Item 2 - Yet Another Item - Menu Item 3 - Menu Item 4 --- # InnoSer International B.V 123 Main Street, City, State 11111 Copyright © 2026, ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "admin", "url" : "https://resources.innoserlaboratories.com/innoser-news/author/admin" }, "dateModified" : "2023-07-14T10:13:49.810Z", "datePublished" : "2020-03-20T10:28:22.000Z", "headline" : "Press Release: InnoSer continues to deliver critical in-vivo and in-vitro services - InnoSer", "mainEntityOfPage" : { "@id" : "https://resources.innoserlaboratories.com/innoser-news/news/press-release-innoser-continues-to-deliver-critical-in-vivo-and-in-vitro-services", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://resources.innoserlaboratories.com/hubfs/Imported_Blog_Media/Asset-36@3x-1024x155.png" } } } ```